2013 | 1 | 9-12
Article title

Stężenie aneksyny V w surowicy i moczu dzieci z idiopatycznym zespołem nerczycowym

Title variants
Languages of publication
  • Lane JC, Kaskel FJ. Pediatric nephrotic syndrome: from the simple to the complex. Semin Nephrol 2009; 29: 389–398.
  • Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr 2012; 79: 1045–1055.
  • DS. Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124: 747–757.
  • KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; 2 (Suppl. 2).
  • Dragovic D, Rosenstock JL, Wahl SJ. Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol 2005; 63: 1–7.
  • Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome.Kidney Int 2005; 68: 1275–1281.
  • Gipson DS, Chin H, Presler TP, et al. Differential risk of remission and ESR D in childhood FSGS. Pediatr Nephrol 2006; 21:344–349.
  • Chugh SS , Clement LC, Macé C. New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis 2012; 59: 284–292.
  • Tait JF, Gibson D. Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 1992; 298(1): 187–191.
  • Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 2011; 23(2): 194–200.
  • Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82(2): 331–371.
  • Markoff A, Gerke V. Expression and functions of annexins in the kidney. Am J Physiol Renal Physiol 2005; 289(5): F949–F956.
  • Marchewka Z. Low molecular weight biomarkers in the nephrotoxicity. Adv Clin Exp Med 2006; 15(6): 1129–1138.
  • Wever KE, Wagener FA, Frielink C, et al. Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS One 2011; 6(8): e24276. doi: 10.1371/journal.pone.0024276.
  • Matsuda R, Kaneko N, Horikawa Y, et al. Measurement of urinary annexin V by ELIS A and its significance as a new urinarymarker of kidney disease. Clin Chim Acta 2000; 298(1–2): 29–43.
  • Simsek B, Buyukcelik M, Soran M, et al. Urinary annexin V in children with nephrotic syndrome: a new prognostic marker? Pediatr Nephrol 2008; 23(1): 79–82.
  • Kaneko N, Matsuda R, Hosoda S, et al. Measurement of plasma annexin V by ELIS A in the early detection of acute myocardial infarction. Clin Chim Acta 1996; 251: 65–80.
  • Kaneko N, Matsuda R, Chiwaki F, et al. Purification of cardiac annexin V from the beagle dog heart and changes in its localization in the ischemic rat heart. Heart Vessels 1994; 9(3): 148–154.
  • Schlaepfer DD, Mehlman T, Burgess WH, et al. Structural and functional characterization of endonexin II , a calcium- and phospholipid-binding protein. Proc Natl Acad Sci USA 1987; 84(17): 6078–6082.
  • Matsuda R, Kaneko N, Horikawa Y, et al. Localization of annexin V in rat normal kidney and experimental glomerulonephritis.Res Exp Med (Berl) 2001; 200(2): 77–92.
  • Hewitt I, House A, Potter J, et al. Altered in vitro lymphocyte response in childhood nephrotic syndrome. Pediatr Nephrol 1992; 6: 464–466.
  • Ishimoto T, Shimada M, Araya CE, et al. Minimal change disease: a CD80 podocytopathy? Semin Nephrol 2011; 31: 320–325.
  • Jefferson JA, Nelson PJ, Najafian B, et al. Podocyte disorders: Core Curriculum 2011. Am J Kidney Dis 2011; 58: 666–677.
  • Zhang SY , Audard V, Fan Q, et al. Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol 2011; 169:194–196.
  • Tudpor K, Laínez S, Kwakernaak AJ, et al. Urinary plasmin inhibits TR PV5 in nephrotic-range proteinuria. J Am Soc Nephrol 2012; 23(11): 1824–1834.
  • Schlaepfer DD, Jones J, Haigler HT. Inhibition of protein kinase C by annexin V. Biochemistry 1992 Feb. 18; 31(6): 1886–1891
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.